Leukemia News

The FDA cleared investigational new drug applications for three cell therapies in development for oncology indications.

Septic shock remained significantly associated with increased 28-day mortality among patients with hematologic malignancies, according to study results published in Journal of the National Comprehensive Cancer Network.

Faith E. Davies, MD, has been appointed the inaugural director of Center for Blood Cancers at NYU Langone Health’s Perlmutter Cancer Center.

The FDA is investigating a possible increased mortality risk with umbralisib, approved in the United States for treatment of two types of lymphoma.

President Joe Biden has unfinished business with cancer.

Children with acute promyelocytic leukemia achieved survival benefit with an all-trans retinoic acid and arsenic trioxide chemotherapy-free regimen, according to study results published in JAMA Oncology.

B-cell acute lymphoblastic leukemia is the most common type of cancer among children.

The FDA granted orphan drug designation to CNCT19, a chimeric antigen receptor T-cell therapy for the treatment of relapsed or refractory acute lymphoblastic leukemia.

Gilead Sciences has decided to voluntarily withdraw its accelerated approval of idelalisib for two blood cancer indications.

An enhanced lymphodepletion regimen followed by chimeric antigen receptor T-cell therapy induced response among patients with relapsed or refractory B-cell malignancies, according to results presented at ASH Annual Meeting and Exposition.